AKT-IN-6 is a potent pan‑AKT (Akt1/2/3) small molecule inhibitor with an in vitro IC50 of less than 500nM for all three AKT isoforms [1]. AKT-IN-6 is primarily used to study the regulation of AKT activity in the PI3K/Akt/mTOR signaling pathway and its role in disease models such as cancer and metabolic diseases [2-3].
In tilapia S. agalactiae infection model, Treatment with AKT-IN-6 (1mg/kg; ip; 2d) significantly reduced the expression and phosphorylation levels of IKKα/β, IκBα, and NF-κB p65 [4].
References:
[1]. Huang T, Feng H, Kong L, et al. Isoindolinone and pyrrolopyridinone derivatives as Akt inhibitors. United States patent US 8,895,571. 2014 Nov 25.
[2]. Manning BD, Cantley LC. AKT/PKB signaling: navigating downstream. Cell. 2007 Jun 29; 129(7): 1261-1274.
[3]. Castro D, Castaner R, Fernandez-Forner D. NME Digest-January 2016. Drugs of the Future. 2016; 41(1).
[4]. Mu L, Li J, Lin Z, et al. MBL regulates phagocytosis and bactericidal activity of macrophages by triggering AKT/NF-κB/Rab5A axis occurred early in vertebrate evolution. The Journal of Immunology. 2025 Apr 25: vkaf028.
AKT-IN-6是一种强效的泛AKT（Akt1/2/3）小分子抑制剂，体外对三种AKT亚型的IC50均小于500nM [1]。AKT-IN-6主要用于研究PI3K/Akt/mTOR信号通路中AKT活性的调控及其在癌症和代谢性疾病等疾病模型中的作用 [2-3]。
在罗非鱼的S. agalactiae感染模型中，AKT-IN-6（1mg/kg；op；2d）治疗显著降低了IKKα/β、IκBα和NF-κB p65的表达和磷酸化水平 [4]。